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Evidence-Based ReviewAmong the primary objectives of the American
Society for Blood and Marrow Transplantation
(ASBMT) are to:
- Define commonly accepted medical and evidence-
based practice
- Develop standards of medical care for autologous
and allogeneic transplants
- Provide recommendations for physicians, patients,
and third-party payers on the role of transplantation
as a therapeutic approach.
Toward this end, in 1999, the Society began spon-
soring evidence-based reviews (EBRs) of the scientific
and medical literature to document when blood and
marrow transplantation is indicated in the treatment
of selected diseases.
In 2009, the ASBMT EBR Steering Committee
determined that previously published reviews should
be updated regularly, at approximately 5-year inter-
vals. The diffuse large B cell lymphoma (DLBCL)
EBR is the first in the series to be updated.GOALS
The goals of the EBRs are to:
- Determine which disease will be the subject of each
review, establish the focus for each review, and
develop a list of questions to be addressed
- Assemble and critically evaluate all valid, peer-
reviewed evidence regarding the role of cytotoxic
therapy with hematopoietic stem cell transplanta-
tion (SCT) related to the disease
- Provide treatment recommendations based on the
available evidence
- Identify discrepancies in study design or methodol-
ogy among published studies that may impact the
quality of the evidence
- Identify areas of needed research./$36.00
6/j.bbmt.2010.11.001The goals of the DLBCL EBR update are to:
- Provide a summary of recent clinical evidence
- Provide timely treatment recommendations
- Determine if new evidence strengthens or changes
treatment recommendations provided in the origi-
nal DLBCL EBR published in 2001.UPDATED TREATMENT RECOMMENDATIONS
FOR DLBCL
The following updated treatment recommenda-
tions are offered for the role of SCT as treatment for
DLBCL, and are based on consensus reached by an
expert panel1 following a systematic review of the liter-
ature published since the 2001 original EBR.2Autologous SCT versus Nontransplantation
Therapy
1. Autologous SCTprovides a significant survival bene-
fit and is recommended as part of salvage therapy
for patients with chemosensitive relapsed DLBCL.
This original recommendation is unchanged, with
no new data published since the original EBR.
2. Autologous SCT is not recommended for patients
who achieve only a partial response to an abbrevi-
ated (3 cycles) induction regimen. This original
recommendation is unchanged, with no new data
published since the original EBR.
3. Based on new data published since the original EBR,
autologous SCT as first-line therapy is not recom-
mended for any International Prognostic Index
group at this time; however, none of the published
studies included rituximab in their treatment proto-
cols. Ongoing studies that include rituximab may
change this recommendation.Autologous SCT: Timing and Protocol
1. Based on new data published since the original
EBR, older age (.60 years), in and of itself, is not
a contraindication for autologous SCT as long as
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limit has been defined. However, SCT outcomes
(transplant-related mortality, relapse, survival) in
older adults are not as good as in younger adults.
2. Based on new data published since the original EBR,
autologous SCT using peripheral blood, compared
to bone marrow, provides no survival benefit or im-
proved tumor control. However, autologous SCT
using peripheral blood is safer and easier to use
with faster engraftment and lower rate of death be-
cause of infection; hence, peripheral blood is the
standard autologous stem cell source.
3. Based on new data published since the original
EBR, planned tandem, ormultiple sequential autol-
ogous SCTs are not recommended.
4. The new data published since the original EBR are
insufficient to recommend routine post-autologous
SCTmaintenancewith rituximaboutside of a clinical
trial.
5. The new data published since the original EBR are
insufficient to make a treatment recommendation
regarding fewer versus more cycles of induction
therapy prior to first-line autologous SCT.Autologous versus Allogeneic SCT
Based on new data published since the original
EBR, there are equivalent survival outcomes after
autologous and allogeneic SCT. Neither donor option
is recommended over the other because they have
competing risks with regard to relapse and transplant-
related mortality. Comparison of these two techniques
is biased by different patient selection criteria.Allogeneic SCT: Conditioning
The new data published since the original EBR are
insufficient to recommend reduced intensity versus
myeloablative conditioning for allogeneic SCT. Based
on one study and expert opinion, reduced intensity con-
ditioning (RIC) appears to be an acceptable alternative
approach for selected patients who cannot tolerate
a myeloablative allogeneic SCT. Longer follow-up is
needed to clarify the competing risks of relapse and
chronic graft-versus-host disease (cGVHD) and their
impact on overall survival (OS) and quality of life.
Comparison of these regimen intensities is biased by
patient selection criteria which have changed over time.AREAS OF NEEDED RESEARCH
After reviewing the updated evidence, the expert
panel identified the following important areas of
needed research in DLBCL:
1. Identify more effective induction regimens to
optimize disease response and reduce the need for
autologous SCT.
2. Identify and examine the efficacy of predictive tests
(ie, positron emission tomography scans) to classify
patients who are at high risk for early treatment
failure (those who are primary refractory to initial
therapies and those who respond but quickly
relapse) and candidates for autologous SCT.
3. Update the International Prognostic Index to in-
clude molecular markers and/or gene expression
profiling to better discriminate prognostic groups
that would benefit from SCT.
4. Determine the potential benefit of first-line autolo-
gous SCT for patients with central nervous system
involvement.
5. Identify effective salvage regimens to optimize dis-
ease response prior to autologous SCT.
6. Identify effective high-dose therapy regimens to
optimize complete response, improve hematopoi-
etic recovery, and reduce transplant-relatedmortal-
ity and incidence of secondary malignancies.
7. Identify effective maintenance regimens to optimize
disease control post-autologous SCT.
8. Examine the efficacy of reduced intensity allogeneic
SCT as rescue after a failed autologous SCT.
1Expert panel members and authors of the review are: Denise M.
Oliansky, Roswell Park Cancer Institute (RPCI), Buffalo, NY;
Myron Czuczman, RPCI, Buffalo, NY, Richard I. Fisher, University
of Rochester, James P. Wilmot Cancer Center, Rochester, NY;
Frank D. Irwin, Optum Health Care Solutions, Minneapolis, MN;
HillardM. Lazarus, CaseComprehensiveCancer Center,University
Hospitals Case Medical Center, Case Western Reserve University,
Cleveland, OH; James Omel, Independent Patient Advocate, Grand
Island, NE; Julie Vose, University of Nebraska Medical Center,
Omaha, NE; Steven N. Wolff, Meharry Medical College and
Vanderbilt University, Nashville, TN; Roy B. Jones, MD Anderson
Cancer Center, Houston, TX; Philip L. McCarthy, Jr., RPCI,
Buffalo NY; Theresa Hahn, RPCI, Buffalo, NY.
2Reference: Oliansky DM, CzuczmanM, Fisher RI, et al. The role of
cytotoxic therapy with hematopoietic stem cell transplantation in the
treatment of diffuse large B cell lymphoma: update of the 2001
evidence-basedreview.BiolBloodMarrowTransplant. 2011;17(1):20-47.
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